SCHEMBL19366374

SCHEMBL19366374

CCC1CCc2cc(OCc3cccnc3)ccc2C1C(C)(C)C

nearest known ligand 0.51

Predicted protein targets (top 17)

geneUniProtsupporting neighboursconfidence
CYP1A1 P04798 1/20 0.51
CYP1B1 Q16678 1/20 0.51
HRH3 Q9Y5N1 1/20 0.48
NPY5R Q15761 3/20 0.40
GPR132 Q9UNW8 3/20 0.40
BRD4 O60885 1/20 0.40
CREBBP Q92793 1/20 0.40
GRM2 Q14416 1/20 0.40
TRPV1 Q8NER1 1/20 0.40
CSF1R P07333 1/20 0.39
GPR84 Q9NQS5 1/20 0.39
PPARD Q03181 1/20 0.39
PPARA Q07869 1/20 0.39
MAOA P21397 1/20 0.39
DYRK1A Q13627 1/20 0.39
MAPK1 P28482 1/20 0.39
HSD17B10 Q99714 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL19366472 0.87 HRH3 (0.45) CYP1A1CYP1B1HRH3BRD4CREBBP
SCHEMBL17531488 0.85 CYP1A1 (0.51) CYP1A1CYP1B1HRH3GPR132BRD4
SCHEMBL19067934 0.84 HSD17B10 (0.44) MAPK1HSD17B10
SCHEMBL19366288 0.81 HRH3 (0.47) HRH3BRD4CREBBPGPR84PPARA
SCHEMBL17538294 0.78 CYP1A1 (0.56) CYP1A1CYP1B1HRH3GPR132BRD4
SCHEMBL19366298 0.76 ALDH1A1 (0.36)
SCHEMBL17531489 0.72 HRH3 (0.44) CYP1A1CYP1B1HRH3BRD4CREBBP
SCHEMBL19067961 0.71 ESR1 (0.47)
SCHEMBL19067937 0.71 PLK1 (0.40) MAOA
SCHEMBL19675327 0.70 CYP1A1 (0.47) CYP1A1CYP1B1HRH3GPR132BRD4

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-10617685-B2 Nonsteroidal and steroidal compounds with potent androgen receptor down-regulation and anti prostate cancer activity UNIVERSITY OF MARYLAND, BALTIMORE (US) 2020-04-14 US disclosed
US-20170266181-A1 NONSTEROIDAL AND STEROIDAL COMPOUNDS WITH POTENT ANDROGEN RECEPTOR DOWN-REGULATION AND ANTI PROSTATE CANCER ACTIVITY UNIVERSITY OF MARYLAND, BALTIMORE (US) 2017-09-21 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-10617685-B2 Nonsteroidal and steroidal compounds with potent androgen receptor down-regulation and anti prostate cancer activity AR, NR5A1, BRCA1 CYP1A1 2105/4885CYP1B1 1022/4885HRH3 4174/4885
US-20170266181-A1 NONSTEROIDAL AND STEROIDAL COMPOUNDS WITH POTENT ANDROGEN RECEPTOR DOWN-REGULATION AND ANTI PROSTATE CANCER ACTIVITY AR, NR5A1, BRCA1 CYP1A1 2105/4885CYP1B1 1022/4885HRH3 4174/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.